WASHINGTON — The Biden administration announced Friday that it is investing in three potential vaccines and a range of new technologies aimed at staying ahead of Covid-19.
The $500 million investment across 13 projects is the latest installment in the federal government’s Project NextGen, a $5 billion plan to develop new Covid-19 treatments, vaccines, and ways of delivering them. The Health and Human Services Department this summer channeled $1.4 billion to similar goals.
Friday’s announcement includes $8.5 million for New York-based CastleVax to develop an intranasal vaccine and $10 million to Codagenix, also in New York, for a live-attenuated intranasal vaccine that it is working on with the Serum Institute of India, one of the largest vaccine producers in the world. HHS also allotted $10 million to Gritstone Bio, the first installment of what could be a massive $433 million investment in the small California biotech’s plans for a “self-amplifying mRNA” vaccine.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect